Agenus (AGEN) : Traders are bullish on Agenus (AGEN) as it has outperformed the S&P 500 by a wide margin of 29.34% in the past 4 weeks. The bullishness in the stock continues even in the near-term as the stock has returned an impressive 0.92%, relative to the S&P 500. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 0.97% in the last 1 week, and is up 30.67% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock.
The stock has recorded a 20-day Moving Average of 16.81% and the 50-Day Moving Average is 32.87%. Agenus (NASDAQ:AGEN): stock turned positive on Friday. Though the stock opened at $5.86, the bulls momentum made the stock top out at $6.24 level for the day. The stock recorded a low of $5.86 and closed the trading day at $6.22, in the green by 4.71%. The total traded volume for the day was 1,498,099. The stock had closed at $5.94 in the previous days trading.
The company Insiders own 7.6% of Agenus shares according to the proxy statements. Institutional Investors own 41.69% of Agenus shares. During last six month period, the net percent change held by insiders has seen a change of 32.06%. Also, Jefferies maintains its rating on Agenus (NASDAQ:AGEN). The global brokerage major raises the current price target from $6 per share to $7 per share. Analysts at the Jefferies have a current rating of Buy on the shares. The rating by the firm was issued on July 29, 2016.
Agenus Inc. (Agenus) is an immunotherapy company. The Company is engaged in discovering and developing treatments for patients with cancer and other diseases. Its approaches are driven by three platform technologies: Its antibody platform, including Retrocyte Display technology, which is designed to produce human monoclonal antibodies focused on advancing checkpoint modulators (CPMs); its heat shock protein (HSP)-based vaccines, and its saponin-based vaccine adjuvants, QS-21 Stimulon adjuvant (QS-21 Stimulon). The Company has a portfolio of programs in pre-clinical and clinical stages, including a series of CPMs in investigational new drug (IND)-enabling studies, Prophage Series vaccine, a Phase III ready HSP-based autologous vaccine for glioblastoma multiforme (GBM), which is a form of brain cancer, and a number of QS-21 Stimulon-containing vaccine candidates in late stage development by its partner, GlaxoSmithKline (GSK).